We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Acorda (ACOR) to Post Q2 Earnings: What's in the Cards?
Read MoreHide Full Article
Acorda Therapeutics, Inc. is scheduled to report second-quarter 2019 results on Aug 1, after the market closes.
Acorda has an excellent earnings surprise history, surpassing expectations in each of the trailing four quarters, the average being 79.32%. In the last reported quarter, the company delivered a positive surprise of 42.27%.
Shares of Acorda have plunged 56.2% so far this year against the industry’s rise of 0.3%.
Let’s see how things are shaping up for this announcement.
Factors to Consider
Last December, the FDA approved Acorda’s Parkinson's disease (PD) drug Inbrija. Following this nod, the product became the first and the only approved inhaled levodopa for the treatment of OFF periods in patients suffering Parkinson’s and receiving a carbidopa / levodopa regimen. The drug was launched in February this year and registered its first sales in the last reported quarter. It is also under review in Europe with a decision expected before 2019 end.
In the first quarter of 2019, Inbrija generated sales of $1.3 million. Acorda believes that Inbrija sales will pick up in the future quarters as well, having received an encouraging feedback both from doctors and patients since its launch. An approximately 2,000 prescription request forms for Inbrija were received through April 2019. We expect this positive trend to get reflected in the upcoming quarterly results.
However, Acorda’s key multiple sclerosis drug Ampyra is facing a generic competition, which is significantly hurting the company’s top line. Notably, in the first quarter of 2019, sales of Ampyra tanked 61% year over year and 37.5% sequentially due to generic launches.
Mylan launched its authorized generic version of Ampyra last September after the U.S. Court of Appeals invalidated four patents of Ampyra. Acorda believes that Ampyra sales will see a sharp decline in the future quarters during 2019. We expect management to provide an update on the same during the upcoming earnings call.
Although Inbrija is off to a promising start, it still remains to be seen if the product can deliver the desired results and be a worthy replacement for Ampyra in the long run. Acorda estimates Inbrija’s market opportunity to be more than $800 million in the United States.
Earnings Whispers
Our proven model does not conclusively show that Acorda is likely to beat estimates this quarter to be reported. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to be able to beat on earnings. But that is not the case here as you will see below.
Earnings ESP: Acordahas an Earnings ESP of -9.01%, representing the percentage difference between the Most Accurate Estimate of a loss of $1.15 and the Zacks Consensus Estimate of a loss of $1.06. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Acorda sports a Zacks Rank of 1, which increases the predictive power of ESP. However, its negative ESP in the combination leaves surprise prediction inconclusive.
We caution against the Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) has a Zacks Rank #3 and an Earnings ESP of +6.25%. The company is scheduled to release second-quarter results on Aug 6, before the market opens.
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Image: Bigstock
Acorda (ACOR) to Post Q2 Earnings: What's in the Cards?
Acorda Therapeutics, Inc. is scheduled to report second-quarter 2019 results on Aug 1, after the market closes.
Acorda has an excellent earnings surprise history, surpassing expectations in each of the trailing four quarters, the average being 79.32%. In the last reported quarter, the company delivered a positive surprise of 42.27%.
Shares of Acorda have plunged 56.2% so far this year against the industry’s rise of 0.3%.
Let’s see how things are shaping up for this announcement.
Factors to Consider
Last December, the FDA approved Acorda’s Parkinson's disease (PD) drug Inbrija. Following this nod, the product became the first and the only approved inhaled levodopa for the treatment of OFF periods in patients suffering Parkinson’s and receiving a carbidopa / levodopa regimen. The drug was launched in February this year and registered its first sales in the last reported quarter. It is also under review in Europe with a decision expected before 2019 end.
In the first quarter of 2019, Inbrija generated sales of $1.3 million. Acorda believes that Inbrija sales will pick up in the future quarters as well, having received an encouraging feedback both from doctors and patients since its launch. An approximately 2,000 prescription request forms for Inbrija were received through April 2019. We expect this positive trend to get reflected in the upcoming quarterly results.
However, Acorda’s key multiple sclerosis drug Ampyra is facing a generic competition, which is significantly hurting the company’s top line. Notably, in the first quarter of 2019, sales of Ampyra tanked 61% year over year and 37.5% sequentially due to generic launches.
Mylan launched its authorized generic version of Ampyra last September after the U.S. Court of Appeals invalidated four patents of Ampyra. Acorda believes that Ampyra sales will see a sharp decline in the future quarters during 2019. We expect management to provide an update on the same during the upcoming earnings call.
Although Inbrija is off to a promising start, it still remains to be seen if the product can deliver the desired results and be a worthy replacement for Ampyra in the long run. Acorda estimates Inbrija’s market opportunity to be more than $800 million in the United States.
Earnings Whispers
Our proven model does not conclusively show that Acorda is likely to beat estimates this quarter to be reported. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to be able to beat on earnings. But that is not the case here as you will see below.
Earnings ESP: Acordahas an Earnings ESP of -9.01%, representing the percentage difference between the Most Accurate Estimate of a loss of $1.15 and the Zacks Consensus Estimate of a loss of $1.06. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Acorda sports a Zacks Rank of 1, which increases the predictive power of ESP. However, its negative ESP in the combination leaves surprise prediction inconclusive.
We caution against the Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Acorda Therapeutics, Inc. Price and EPS Surprise
Acorda Therapeutics, Inc. price-eps-surprise | Acorda Therapeutics, Inc. Quote
Stocks That Warrant a Look
Here are some biotech stocks worth considering as our model shows that these have the right mix of elements to beat on earnings this reporting cycle.
Gilead Sciences, Inc. (GILD - Free Report) is scheduled to release second-quarter results on Jul 30, after the market closes. The company has an Earnings ESP of +3.20% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) has a Zacks Rank #3 and an Earnings ESP of +6.25%. The company is scheduled to release second-quarter results on Aug 6, before the market opens.
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Click here to see these breakthrough stocks now >>